Efficacy and Safety of 6-Weekly versus 12-Weekly Intravenous Methylprednisolone in Moderate-to-Severe Active Thyroid-Associated Ophthalmopathy.
Kenneth Ka Hei LaiFatema Mohamed Ali Abdulla AljufairiChi Lai LiAmanda K Y NgaiCarly S K YeungRyan H Y FongWilson W K YipAlvin L YoungChi Pui PangKelvin Kam-Lung ChongPublished in: Journal of clinical medicine (2023)
= 0.0193) than those who required additional treatment. The total numbers of adverse events were comparable between the two groups.